Chargement de votre page…
Pain research & management
Par Bianco A, Lucchini M, Sottani C et 8 autres.
Contenu en anglais
Headache associated with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is poorly characterized.
Ward réunit ces articles dans la même app que vos cartes et vos questions. Un seul compte gratuit pour Ward, Suture, Osler et Prognia.
To investigate the prevalence, clinical phenotypes, and longitudinal evolution of headache in MOGAD.
In this single-center retrospective cohort study based on prospectively collected clinical data, consecutive adult patients diagnosed with MOGAD between 2020 and 2024 were enrolled. Demographic, clinical, and radiological data were collected. Headaches were classified according to the International Classification of Headache Disorders. Patients underwent quarterly evaluations over 1 year. Pain severity was assessed using the Numeric Rating Scale at baseline and at the 1-year visit, while headache-related disability was assessed using the Migraine Disability Assessment at the 1-year visit in patients reporting headache.
Twenty-two patients were included (median age 35 years; 54.5% male). Headache occurred in 54.5% at onset and 68.2% after 1 year. Pre-existing primary headache disorders were present in 54.5%. Headaches showed heterogeneous features, commonly retro-orbital or unilateral frontal pain with pulsating or pressure-like quality and associated photophobia/phonophobia. Migraine was the predominant phenotype at 1 year. Headache characteristics evolved over time in 73.7% of the cases, while 50% reported inadequate response to symptomatic therapy. Female sex, pre-existing headache, and rituximab exposure were associated with headache persistence in univariable analyses.
Headache is common in MOGAD, often pre-existing, with heterogeneous phenotypes, although its clinical burden and evolution over time remain incompletely characterized. New-onset retro-orbital headache may represent a clinical red flag requiring further investigation.
ClinicalTrials.gov identifier: NCT07479212.
Publié dans Pain research & management. Le résumé est reproduit tel qu’il a été publié et reste l’œuvre de ses auteurs ; lisez l’article complet à la source.
Prognia référence cet article à des fins de documentation et de formation. Il ne constitue pas un avis médical. Lisez toujours l’original et suivez les recommandations en vigueur et les protocoles locaux avant d’agir.
